ResMed rising as Cochlear faces pressure
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
Once both market darlings, ResMed (RMD) and Cochlear (COH) appear to be on divergent performance paths.
ResMed shares soared late last week after the sleep and breathing disorder device manufacturer unveiled an 11% lift in fourth-quarter revenue despite challenging market conditions.
Hearing device manufacturer Cochlear, by contrast, is expected to come under pressure ahead of its full-year earnings release tomorrow after a series of technical and regulatory problems resulting in product recalls for its Nucleus 5 product.
Under pressure from a Chinese rival, the company’s latest device Nucleus 6 has attracted strong forward orders that will only deliver revenue in the year ahead.
Cochlear is trading on a rather heroic price multiple of 25 times its 2013 earnings and 23 times this year’s forecast profit and, given its lofty pricing, is almost universally recommended as a sell.
Its pricing has been supported by a relatively attractive dividend of 4.3% but its ability to maintain that kind of payout given the difficulties of the past year remains under a cloud.
Resmed, by contrast, is in the ascendancy. On Friday it posted its 74th consecutive quarter of revenue growth while earnings outstripped consensus estimates by around 15%.
Its margins also expanded and with around 95% of its earnings offshore, it stands to be a major beneficiary of a weakening Australian dollar (see Shane Oliver's Time to go global).
Its European division performed far better than expected particularly in Germany which had been considered a problem.
While it is stratospheric pricing – at 24.2 times 2013 earnings - is similar to Cochlear, it is the growth potential that marks the difference between the pair.
Cochlear easily beats ResMed as a dividend play, with ResMed delivering a yield of just 1.4%.
In an interesting twist given the obsession with yield, when it comes to medical devices it appears investors prefer growth.
Call 1300 880 160
Start a chat
Schedule a call
